Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2002-08-20
2010-02-23
Helms, Larry R. (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S069700, C530S412000
Reexamination Certificate
active
07666581
ABSTRACT:
The present invention relates to methods and compositions for the prevention and treatment of infectious diseases, and cancers. The methods of the invention comprises complexing a population of antigenic proteins or antigenic peptides derived from antigenic cells or viral particles to one or more different heat shock proteins in vitro. The population or the protein preparation used to produce the antigenic peptides comprises at least 50% of the different proteins or at least 50 different proteins of the antigenic cells or viral particles. Methods for making antigenic peptides comprise digesting a protein preparation of antigenic cells, a cellular fraction thereof, or of viral particles with one or more proteases, or exposing the protein preparation to ATP, guanidium hydrochloride, and/or acidic conditions.
REFERENCES:
patent: 4690915 (1987-09-01), Rosenberg
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5232833 (1993-08-01), Sanders et al.
patent: 5348945 (1994-09-01), Berberian et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5652115 (1997-07-01), Marks et al.
patent: 5736146 (1998-04-01), Cohen et al.
patent: 5747332 (1998-05-01), Wallen et al.
patent: 5750119 (1998-05-01), Srivastava
patent: 5830464 (1998-11-01), Srivastava
patent: 5837251 (1998-11-01), Srivastava
patent: 5856201 (1999-01-01), Shoseyov et al.
patent: 5869058 (1999-02-01), Cohen
patent: 5891653 (1999-04-01), Attfield
patent: 5935576 (1999-08-01), Srivastava
patent: 5947646 (1999-09-01), Lytle
patent: 5948646 (1999-09-01), Srivastava et al.
patent: 5961979 (1999-10-01), Srivastava
patent: 5985270 (1999-11-01), Srivastava
patent: 5997873 (1999-12-01), Srivastava
patent: 6017540 (2000-01-01), Srivastava
patent: 6030618 (2000-02-01), Srivastava
patent: 6048530 (2000-04-01), Srivastava
patent: 6136315 (2000-10-01), Srivastava
patent: 6162436 (2000-12-01), Srivastava
patent: 6168793 (2001-01-01), Srivastava et al.
patent: 6187312 (2001-02-01), Srivastava
patent: 6312711 (2001-11-01), Duchateau et al.
patent: 6338945 (2002-01-01), Nicolette
patent: 6399070 (2002-06-01), Srivastava et al.
patent: 6403092 (2002-06-01), Pizzo et al.
patent: 6433141 (2002-08-01), Wallen et al.
patent: 6689363 (2004-02-01), Sette et al.
patent: 6709672 (2004-03-01), Henot et al.
patent: 6713608 (2004-03-01), Wallen et al.
patent: 6730302 (2004-05-01), Fujihara et al.
patent: 6797480 (2004-09-01), Srivastava
patent: 2002/0028207 (2002-03-01), Srivastava
patent: 2002/0037290 (2002-03-01), Armen
patent: 2002/0172682 (2002-11-01), Srivastava
patent: 2002/0192230 (2002-12-01), Srivastava
patent: 2003/0211971 (2003-11-01), Srivastava
patent: 2004/0253228 (2004-12-01), Srivastava
patent: 196 02 985 (1996-01-01), None
patent: 2 251 186 (1992-07-01), None
patent: WO 89/12455 (1989-12-01), None
patent: WO 90/02564 (1990-03-01), None
patent: WO 91/15572 (1991-10-01), None
patent: WO 92/01717 (1992-02-01), None
patent: WO 92/08484 (1992-05-01), None
patent: WO 92/08488 (1992-05-01), None
patent: WO 93/14118 (1993-07-01), None
patent: WO 93/17712 (1993-09-01), None
patent: WO 93/18146 (1993-09-01), None
patent: WO 93/18147 (1993-09-01), None
patent: WO 93/18150 (1993-09-01), None
patent: WO 93/21529 (1993-10-01), None
patent: WO 93/24136 (1993-12-01), None
patent: WO 94/03208 (1994-02-01), None
patent: WO 94/04676 (1994-03-01), None
patent: WO 94/11513 (1994-05-01), None
patent: WO 94/14976 (1994-07-01), None
patent: WO94/14976 (1994-07-01), None
patent: WO 94/29459 (1994-12-01), None
patent: WO 95/24923 (1995-09-01), None
patent: WO 96/10411 (1996-04-01), None
patent: WO 97/06685 (1997-02-01), None
patent: WO 97/06821 (1997-02-01), None
patent: WO 97/06828 (1997-02-01), None
patent: WO 97/10000 (1997-03-01), None
patent: WO 97/10001 (1997-03-01), None
patent: WO 97/10002 (1997-03-01), None
patent: WO 97/26910 (1997-07-01), None
patent: WO 98/46743 (1998-10-01), None
patent: WO 99/29834 (1999-06-01), None
patent: WO 99/50303 (1999-10-01), None
patent: WO 00/54801 (2000-09-01), None
patent: WO 01/91787 (2001-06-01), None
patent: WO 01/92474 (2001-12-01), None
patent: WO 02/15930 (2002-02-01), None
patent: WO 02/30434 (2002-04-01), None
patent: WO 02/32923 (2002-04-01), None
patent: WO 02/34205 (2002-05-01), None
patent: WO 03/090686 (2003-11-01), None
patent: WO 03/092624 (2003-11-01), None
patent: WO 2004/075636 (2004-09-01), None
Deutscher et al., Guide to protein purification, Method in enzymology, vol. 182.
Xiao et al., (Archives of Biochemistry and biophysics, vol. 320, p. 96-105, 1995).
Ojcius et al., J of Immunology, vol. 152, p. 2798-2810, 1994.
Mazzoni et al., JBC, vol. 266, p. 14072-14081, 1991.
Elliott Shaw Method of Enzymology, vol. 25, p. 655-660, 1972.
Bartlett, 1972 “Effect Of Host Immunity On The Antigenic Strength Of Primary Tumors.”J. Natl. Cancer Inst. 49:493-504.
Beverly, 1988, “Tumour Immunology.” In:Immunology, 3rd Edition, Roitt, Ed., Mosby, London, pp. 17.1-17.12.
Binder et al., 2002 “Naturally formed or artificially reconstituted non-covalent alpha2-macroglobulin-peptide complexes elicit CD91-dependent cellular immunity.”Cancer Immun. Dec. 18;2:16-24.
Bumol et al., 1988 “Characterization Of The Human Tumor And Normal Tissue Reactivity Of The KS1/4 Monoclonal Antibody.”Hybridoma7:407-415.
Carswell et al., 1970, “Immunogenic Properties Of Reticulum Cell Sarcomas Of SJL/J Mice.”Natl. Cancer Inst. 44:1281-1288.
Cassel et al., 1983 “A Phase II Study On The Postsurgical Management Of Stage II Malignant Melanoma With A Newcastle Disease Virus Oncolysate.”Cancer, 52:856-860.
Dash, et al., 2002 “Slow-Tight Binding Inhibition of Xylanase by an Aspartic Protease Inhibitor.”J. Biol. Chem. 277:17978-17986.
Deutscher et al., 1992 “Guide to protein purification.”Meth. Enzymol., 182:779-780.
Dubois, et al., 1982 “Purification and Biochemical Properties of Tumor-Associated Transplantation Antigens From Methylcholanthrene-Induced Murine Sarcomas.”Proc. Natl. Acad. Sci USA, 79:7669-7673.
Graham, et al. 1955,, “Antibodies Elicited by Cancer in Patients.”,Cancer8:409-416.
Griffen, Jr., et al. 1972, “Colon Carcinoma and Immunologic Phenomena.”Surgical Clinics of North America, vol. 52:839-846.
Grobmann et al., 1997, “Active-Specific Immunotherapy Of Pancreatic Carcinoma: Usefulness Of Human Pancreatic Carcinomas In Preparing Autologous Tumor Vaccines.”Anticancer Res. 17: 3117-3120.
Heiskala et al., 1988 “Characteristics Of Soluble Tumour-Derived Proteins That Inhibit Natural Killer Activity.”Scand. J. Immunol. 28:19-27.
Henttu and Vihko, 1989 “cDNA Coding For The Entire Human Prostate Specific Antigen Shows High Homologies To The Human Tissue Kallikrein Genes.”Biochem. Biophys. Res. Comm. 160:903-910.
Hughes et al., 1970, “A Study In Clinical Cancer Immunotherapy”,Cancer, 26:269-278.
Israeli et al., 1993, “Molecular Cloning Of A Complementary DNA Encoding A Prostate-Specific Membrane Antigen.”Cancer Res. 53:227-230.
Jocham et al.,2004, “Adjuvant Autologous Renal Tumour Cell Vaccine and Risk of Tumour Progression in Patients with Renal-Cell Carcinoma After Radical Nephrectomy: Phase III, Randomised Controlled Trial.”The Lancet, vol. 363:594-599.
Kripke, 1974 “Antigenicity Of Murine Skin Tumors Induced By Ultraviolet Light.”J. Natl. Cancer Inst. 53:1333-1336.
Livingston et al. 1985,, “Serological Response of Melanoma Patients to Vaccines Prepared from VSV Lysates of Autologous and Allogeneic Cultured Melanoma Cells.”Cancer, 55:713-720.
Murray et al., 1977 “Viral Oncolysate in the Management of Malignant Melanoma II, Clinical Studies.”Cancer40:680-686.
Nair et al., 1977 “Antigen-Presenting Cells Pulsed With Unfractionated Tumor-Derived Peptides Are Potent Tumor Vaccines.”Eur. J. Immunol. 27:589-597.
Natali et al., 1987 “Immunohistochemical Detection Of Antigen In Human Primary And Metastatic Melanomas By The Monoclonal Antibody 140.240 A
Helms Larry R.
Jones Day
University of Connecticut Health Center
Yao Lei
LandOfFree
Methods for preparing compositions comprising heat shock... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for preparing compositions comprising heat shock..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for preparing compositions comprising heat shock... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4199421